Megaflox, 400 mg 5 pcs

Lung inflammation (pneumonia), Infectious diseases, Bronchitis, Sinusitis, Respiratory tract infections, Urinary tract infections, Skin infections

Infections of the upper and lower airways: acute sinusitis, exacerbation of chronic bronchitis, outpatient pneumonia; skin and soft tissue infections.

Indications

Infections of the upper and lower respiratory tract: acute sinusitis, exacerbation of chronic bronchitis, community-acquired pneumonia; skin and soft tissue infections.

Pharmacological effect

Antimicrobial agent, fluoroquinolone

Special instructions

Moxifloxacin is prescribed with caution for epileptic syndrome (including a history), epilepsy, liver failure, and long QT interval syndrome.

During fluoroquinolone therapy, inflammation and tendon rupture may develop, especially in elderly patients and in patients simultaneously receiving corticosteroids.

At the first sign of pain or inflammation of the tendons, patients should stop treatment and relieve the affected limb from stress.

Active ingredient

Moxifloxacin

Composition

1 tab. contains moxifloxacin hydrochloride 436.8 mg, which corresponds to the content of moxifloxacin 400 mg

Excipients:

microcrystalline cellulose – 161.2 mg,

povidone (K-30) – 18 mg,

croscarmellose sodium – 70 mg,

colloidal silicon dioxide (Aerosil) – 7 mg,

magnesium stearate – 7 mg.

Film shell composition:

opadry II (episode 85), incl. polyvinyl alcohol – 8.4 mg,

macrogol – 4.242 mg,

talc – 3.108 mg,

titanium dioxide – 4.916 mg,

aluminum varnish based on azorubine dye – 0.094 mg,

aluminum varnish based on solar yellow dye – 0.118 mg.

Contraindications

Children and adolescents up to 18 years of age, pregnancy, lactation (breastfeeding period), hypersensitivity to moxifloxacin.

Use during pregnancy and breastfeeding
Moxifloxacin is contraindicated for use during pregnancy and lactation (breastfeeding).

Use for liver dysfunction
Moxifloxacin should be used with caution in patients with liver failure.

Use in children
Contraindicated in children and adolescents under 18 years of age.

Use in elderly patients
Tendon inflammation and rupture may develop in elderly patients during fluoroquinolone therapy. At the first sign of pain or inflammation of the tendons, patients should stop treatment and relieve the affected limb from stress.

Side Effects

From the digestive system: abdominal pain, nausea, diarrhea, vomiting, dyspepsia, flatulence, constipation, increased activity of liver transaminases, taste perversion.

From the central nervous system and peripheral nervous system: dizziness, insomnia, nervousness, anxiety, asthenia, headache, tremor, paresthesia, leg pain, convulsions, confusion, depression.

From the cardiovascular system: tachycardia, peripheral edema, increased blood pressure, palpitations, chest pain.

Laboratory indicators: decreased prothrombin levels, increased amylase activity.

From the hematopoietic system: leukopenia, eosinophilia, thrombocytosis, thrombocytopenia, anemia.

From the musculoskeletal system: back pain, arthralgia, myalgia.

From the reproductive system: vaginal candidiasis, vaginitis.

Allergic reactions: rash, itching, urticaria.

Interaction

When used simultaneously, antacids, minerals, and multivitamins impair absorption (due to the formation of chelate complexes with polyvalent cations) and reduce the concentration of moxifloxacin in plasma (simultaneous use is possible with an interval of 4 hours before or 2 hours after taking moxifloxacin).

When taking moxifloxacin while using other fluoroquinolones, phototoxic reactions may develop.
Ranitidine reduces the absorption of moxifloxacin.

Manufacturer

Obolenskoye FP JSC, Russia